Bionime Corp
Bionime Corp is a medical equipment and supplies company that generates revenue primarily through the development, manufacturing, and distribution of diagnostic and healthcare products.
Business. Bionime Corp (4737.TW) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, though specific operating segments and geographic breakdowns are not disclosed. Headquartered in Taiwan, the company is primarily listed on the Taiwan Stock Exchange.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Bionime Corp (4737.TW) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, though specific operating segments and geographic breakdowns are not disclosed. Headquartered in Taiwan, the company is primarily listed on the Taiwan Stock Exchange.
Bionime Corp's capital structure is characterized by a high debt-to-equity ratio of 1.49, indicating a significant reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.73, suggesting limited short-term liquidity to cover immediate liabilities. The price-to-book ratio of 2.39 implies that the market values the company at a premium to its book value, but this is not supported by strong profitability metrics.
Profitability metrics for Bionime Corp are weak, with a negative return on equity (ROE) of -1.9% and a return on assets (ROA) of -0.66%. These figures fall below the typical performance benchmarks for the medical equipment and supplies industry, which generally expects positive ROE and ROA. The company reported a net loss of TWD 35.8 million and an operating loss of TWD 51.8 million in the latest period, further highlighting its underperformance.
The company's revenue is not segmented by product or geographic region in the available data, but the high concentration of revenue in a single business line (medical equipment and supplies) suggests potential exposure to market-specific risks. There is no indication of geographic diversification in the financial snapshot, which could limit the company's resilience to regional economic downturns.
Bionime Corp's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. The company's operating cash flow of TWD 16.3 million is modest, and its free cash flow is negative at TWD -72.3 million, indicating that the company is not generating sufficient cash to fund operations and capital expenditures. The capital expenditure of TWD -162.6 million suggests ongoing investment in infrastructure, but this is not offset by positive cash flow generation.
The risk assessment for Bionime Corp highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could constrain its ability to meet short-term obligations. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the company's financial performance and liquidity position suggest that it may need to raise additional capital in the future, which could lead to dilution.
Recent events and filings for Bionime Corp do not provide specific details on strategic initiatives or operational changes. The company's financial performance and liquidity position suggest that it may need to address its operational inefficiencies and debt burden to improve its financial health.
- Bionime Corp has a high debt-to-equity ratio of 1.49, indicating a significant reliance on debt financing.
- The company's profitability metrics are weak, with a negative ROE of -1.9% and a negative ROA of -0.66%.
- Bionime Corp's liquidity position is assessed as medium, with a current ratio of 0.73.
- The company's revenue is concentrated in a single business line, suggesting potential exposure to market-specific risks.
- Bionime Corp's free cash flow is negative at TWD -72.3 million, indicating insufficient cash to fund operations and capital expenditures.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue TWD 471.7M, −0,7% YoY; Operating income +55,7% YoY.
- ▍Revenue TWD 471.7M, −0,7% YoY
- ▍Operating income +55,7% YoY
- ▍Net income +58,8% YoY
- ▍Free cash flow +42,3% YoY
- ▍Net margin -3.1%
Revenue TWD 1.93B; Operating income -TWD 159.2M.
- ▍Revenue TWD 1.93B
- ▍Operating income -TWD 159.2M
- ▍Net margin -6.6%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Bionime Corp Market data — financials · 2026-05-26